CL2012002189A1 - Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. - Google Patents

Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.

Info

Publication number
CL2012002189A1
CL2012002189A1 CL2012002189A CL2012002189A CL2012002189A1 CL 2012002189 A1 CL2012002189 A1 CL 2012002189A1 CL 2012002189 A CL2012002189 A CL 2012002189A CL 2012002189 A CL2012002189 A CL 2012002189A CL 2012002189 A1 CL2012002189 A1 CL 2012002189A1
Authority
CL
Chile
Prior art keywords
carboxamides
cancer
treatment
mdm2
solid tumors
Prior art date
Application number
CL2012002189A
Other languages
English (en)
Inventor
David Joseph Bartkovitz
Xin Jie Chu
Qingjie Ding
Nan Jiang
Jin Jun Liu
Tina Morgan Ross
Jing Zhang
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2012002189A1 publication Critical patent/CL2012002189A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

compuestos derivados de pirrolidina-2-carboxamidas sustituidas; preparación farmacéutica que los comprende; y su uso para el tratamiento del cáncer, en particular, tumores sólidos.
CL2012002189A 2010-02-09 2012-08-07 Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. CL2012002189A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/702,402 US8354444B2 (en) 2008-09-18 2010-02-09 Substituted pyrrolidine-2-carboxamides

Publications (1)

Publication Number Publication Date
CL2012002189A1 true CL2012002189A1 (es) 2012-11-23

Family

ID=43608850

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002189A CL2012002189A1 (es) 2010-02-09 2012-08-07 Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.

Country Status (32)

Country Link
US (1) US8354444B2 (es)
EP (1) EP2534132B1 (es)
JP (1) JP5612710B2 (es)
KR (1) KR101461298B1 (es)
CN (1) CN102753522B (es)
AR (2) AR080143A1 (es)
AU (1) AU2011214506C1 (es)
BR (1) BR112012019672B1 (es)
CA (1) CA2788236C (es)
CL (1) CL2012002189A1 (es)
CR (1) CR20120410A (es)
CY (1) CY1119049T1 (es)
DK (1) DK2534132T3 (es)
EC (1) ECSP12012083A (es)
ES (1) ES2629439T3 (es)
HK (1) HK1171452A1 (es)
HR (1) HRP20170903T1 (es)
HU (1) HUE034816T2 (es)
LT (1) LT2534132T (es)
MX (1) MX2012009186A (es)
MY (1) MY165238A (es)
NZ (1) NZ601422A (es)
PE (1) PE20121532A1 (es)
PL (1) PL2534132T3 (es)
PT (1) PT2534132T (es)
RS (1) RS56163B1 (es)
RU (1) RU2564022C2 (es)
SG (1) SG182763A1 (es)
SI (1) SI2534132T1 (es)
TW (1) TWI401243B (es)
UA (1) UA107954C2 (es)
WO (1) WO2011098398A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7303676B2 (en) * 2003-02-13 2007-12-04 Zenon Technology Partnership Supported biofilm apparatus and process
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CN102638981B (zh) 2009-10-14 2015-07-22 默沙东公司 提高p53活性的取代的哌啶和其用途
US8088815B2 (en) * 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
BR112013023175B1 (pt) 2011-03-10 2022-11-16 Daiichi Sankyo Company, Limited Composto, composição farmacêutica, e, uso do composto
EP2771008A4 (en) 2011-10-28 2015-04-08 Merck Sharp & Dohme MACROCYCLES INCREASING P53 ACTIVITY AND USES THEREOF
WO2013096150A1 (en) 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US20130245089A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
US20140200255A1 (en) * 2012-03-19 2014-07-17 Brian Higgins Method for administration
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
MX2014014229A (es) 2012-05-30 2015-02-17 Hoffmann La Roche Pirrolidina-2-carboxamidas sustituidas.
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
CN104936589A (zh) 2013-01-22 2015-09-23 霍夫曼-拉罗奇有限公司 具有改善的生物利用度的药物组合物
SI2958893T1 (sl) 2013-02-21 2017-08-31 F. Hoffmann-La Roche Ag Asimetrična sinteza substituiranega pirolidin-2-karboksamida
WO2014158638A1 (en) * 2013-03-13 2014-10-02 Dow Agrosciences Llc Preparation of certain (substituted phenyl)-triazolyl-(substituted phenyl) molecules, and intermediates and insecticides related thereto
BR112015030734A2 (pt) * 2013-06-19 2017-07-25 Hoffmann La Roche produto farmacêutico, kit e método de tratamento
CN105307660A (zh) * 2013-06-19 2016-02-03 豪夫迈·罗氏有限公司 用于癌症治疗的ro5503781和卡培他滨的组合
AU2014301324A1 (en) * 2013-06-24 2015-12-10 F. Hoffmann-La Roche Ag Stable intravenous formulation
EP3017061B1 (en) 2013-07-03 2019-01-02 F. Hoffmann-La Roche AG Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist
EP3077004B1 (en) 2013-12-05 2020-02-19 F.Hoffmann-La Roche Ag Novel combination treatment for acute myeloid leukemia (aml)
US9657351B2 (en) 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
KR20160138307A (ko) * 2014-04-15 2016-12-02 에프. 호프만-라 로슈 아게 약학적으로 활성인 화합물의 고체 형태
CN106794171B (zh) 2014-04-17 2020-03-24 密歇根大学董事会 Mdm2抑制剂和使用其的治疗方法
JP6162646B2 (ja) * 2014-05-27 2017-07-12 信越化学工業株式会社 ３，５−ジメチルドデカン酸の製造方法
EP3204776B1 (en) * 2014-10-10 2019-09-04 F.Hoffmann-La Roche Ag Methods for personalizing patient cancer therapy with an mdm2 antagonist
PT3277677T (pt) * 2015-03-30 2021-04-20 Mission Therapeutics Ltd Compostos de 1-ciano-pirrolidina como inibidores de usp30
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
KR102122469B1 (ko) * 2016-11-01 2020-06-12 주식회사 엘지화학 변성 공액디엔계 중합체 및 이의 제조방법
EP3564208B1 (en) 2016-12-30 2021-11-10 Oriental (Luzhou) Agrochemicals. Co., Ltd. Method for preparing 2-(cyclohexenylene) malonic acid derivative and use thereof
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
JOP20200001A1 (ar) 2017-07-11 2022-10-30 Vertex Pharma كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
CN108586195A (zh) * 2017-12-27 2018-09-28 北京汇康博源医药科技有限公司 一种5-羟基-7，7-二甲基-2h-茚酮的制备方法
WO2019213106A1 (en) 2018-04-30 2019-11-07 Teva Pharmaceuticals International Gmbh Solid state forms of idasanutlin
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN116459225B (zh) * 2023-04-26 2023-11-10 东莞市金美济药业有限公司 一种艾拉戈克钠片及其制备工艺

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732902A (en) 1986-05-23 1988-03-22 Hoffmann-La Roche Inc. Pyrroloisoquinolinyl-dimethyloxoalkyl alkonoates and their use as antipsychotic agents
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
JP2001514245A (ja) 1997-08-28 2001-09-11 ファルマシア・アンド・アップジョン・カンパニー タンパク質チロシンホスファターゼ阻害剤
US6482921B1 (en) 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6916833B2 (en) * 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
US7550487B2 (en) * 2004-03-26 2009-06-23 Hoffmann-La Roche Inc. Pyrrolidine-3,4-dicarboxamide derivatives
NZ561215A (en) * 2005-02-22 2010-12-24 Univ Michigan Small molecule inhibitors of MDM2 and uses thereof
CA2598690C (en) 2005-02-22 2011-11-15 The Regents Of The University Of Michigan Small molecule inhibitors of mdm2 and uses thereof
CA2610428A1 (en) 2005-06-17 2006-12-21 Astrazeneca Ab Thrombin inhibiting 2-oxo-1, 2, 5, 6-tetrahydropyridine derivatives
JP2009542666A (ja) * 2006-06-30 2009-12-03 シェーリング コーポレイション Ｐ５３活性を増加させる置換ピペリジンおよびその使用
CA2671861C (en) 2006-12-06 2015-12-29 Sanofi-Aventis Urea and sulfamide derivatives as tafia inhibitors
TW200911787A (en) 2007-07-03 2009-03-16 Astrazeneca Ab New aza-bicyclohexane compounds useful as inhibitors of thrombin
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
US8134001B2 (en) * 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
ES2494390T3 (es) 2008-06-06 2014-09-15 Sanofi Derivados macrocíclicos de urea y de sulfamida como inhibidores de TAFIa
CN102131802A (zh) 2008-06-23 2011-07-20 阿斯利康(瑞典)有限公司 用作凝血酶抑制剂的新型杂环甲酰胺
GB0811643D0 (en) * 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
PE20110367A1 (es) 2008-09-18 2011-06-13 Hoffmann La Roche DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions

Also Published As

Publication number Publication date
AU2011214506B2 (en) 2014-04-17
MX2012009186A (es) 2012-08-23
PL2534132T3 (pl) 2017-09-29
KR20120119922A (ko) 2012-10-31
JP5612710B2 (ja) 2014-10-22
ES2629439T3 (es) 2017-08-09
DK2534132T3 (en) 2017-07-10
US20100152190A1 (en) 2010-06-17
HRP20170903T1 (hr) 2017-09-08
AU2011214506A1 (en) 2012-08-16
RU2012138257A (ru) 2014-03-20
BR112012019672A2 (pt) 2016-05-03
EP2534132B1 (en) 2017-04-26
BR112012019672B1 (pt) 2020-11-17
SG182763A1 (en) 2012-08-30
RS56163B1 (sr) 2017-11-30
KR101461298B1 (ko) 2014-11-28
PT2534132T (pt) 2017-06-26
CA2788236C (en) 2015-01-20
RU2564022C2 (ru) 2015-09-27
ECSP12012083A (es) 2012-09-28
MY165238A (en) 2018-03-14
WO2011098398A1 (en) 2011-08-18
HK1171452A1 (en) 2013-03-28
SI2534132T1 (sl) 2017-08-31
AR114159A2 (es) 2020-07-29
NZ601422A (en) 2014-07-25
US8354444B2 (en) 2013-01-15
TWI401243B (zh) 2013-07-11
JP2013518921A (ja) 2013-05-23
HUE034816T2 (en) 2018-02-28
PE20121532A1 (es) 2012-11-26
CR20120410A (es) 2012-09-05
UA107954C2 (en) 2015-03-10
AU2011214506C1 (en) 2014-07-17
LT2534132T (lt) 2017-07-10
CN102753522B (zh) 2013-11-27
CN102753522A (zh) 2012-10-24
AR080143A1 (es) 2012-03-14
CA2788236A1 (en) 2011-08-18
TW201136892A (en) 2011-11-01
CY1119049T1 (el) 2018-01-10
EP2534132A1 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2015002194A1 (es) Inhbidores de erk y sus usos
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2015002394A1 (es) Inhibidores de histona desmetilasas
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
CL2012001422A1 (es) Compuestos derivados de sulfonil benzamidas sustituidas, inductores de apoptosis con selectividad por bcl-2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.